Lactoferrin Patents (Class 514/2.5)
-
Patent number: 11197917Abstract: Formulations having a protein component, in which the protein contains one or more digestion-aiding proteins, and/or one or more immunoprotective proteins. The formulations may also contain a fat component, a carbohydrate component, and vitamins and minerals. These formulations can be used to provide nutritional support to a subject, either as dietary supplements or as a primary source of nutrition, such as for an infant formula.Type: GrantFiled: December 1, 2017Date of Patent: December 14, 2021Assignee: ByHeart, Inc.Inventors: Ron Belldegrun, Mia Funt
-
Patent number: 11142552Abstract: The present invention relates to a novel protein comprising novel genes that is extracted from Burkholderia gladioli strain NGJ1. A nucleotide sequence encoding the novel protein is represented by sequence SEQ ID No. 1 and amino acid sequence of the novel protein is represented by the sequence SEQ ID No. 2 is further provided. A nucleotide sequence and the amino acid sequence are obtained from genetically engineered Bg_9562 gene. The novel protein as well as encoding gene is adapted for broad spectrum anti-fungal and mycophagous activities.Type: GrantFiled: July 19, 2017Date of Patent: October 12, 2021Inventors: Durga Madhab Swain, Sunil Kumar Yadav, Gopaljee Jha
-
Patent number: 10517918Abstract: The invention relates to modified sweet whey protein (MSWP) for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of MSWP for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and its associated neural pathways) and/or to reverse retardation and/or to prevent retardation of the establishment of cognitive functions. Humans or animals and, in particular, a foetus, pre-term or term born infant, toddler or child or a young adult may benefit from the invention.Type: GrantFiled: December 12, 2014Date of Patent: December 31, 2019Assignee: Societe des Produits Nestle S.A.Inventor: Magali Faure
-
Patent number: 9050323Abstract: Use of at least one transferrin, preferably lactoferrin, for preventing and/or treating destructive inflammation affecting mucous membranes, optionally associated with states of hypoferremia and/or anemia and/or acute and chronic infections. The destructive inflammation is caused, for example, by pathological conditions during pregnancy and by infections sustained by intracellular or adhered or biofilm-protected pathogens. The action of the transferrins described here is achieved by means of their topical and/or oral administration. A combined preparation for simultaneous, sequential or separate use is also described which comprises, as active components, a first composition for topical administration of at least one transferrin and a second composition for oral administration of at least one transferrin.Type: GrantFiled: April 5, 2006Date of Patent: June 9, 2015Assignee: MICROBO S.R.L.Inventors: Piera Valenti, Rosalba Paesano
-
Patent number: 9044466Abstract: Oral compositions and methods of use thereof are provided herein. The oral compositions comprise a first component comprising at least one Eh-raising compound and a pharmaceutically acceptable carrier, and a second component comprising at least one zinc compound, an anti-microbial agent and a pharmaceutically acceptable carrier.Type: GrantFiled: August 5, 2011Date of Patent: June 2, 2015Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Marvin Cohen, Susanne Cohen, Robert G. Flynn
-
Patent number: 8999923Abstract: The invention pertains to an aqueous composition containing lactoferrin, 35-70 wt % carbohydrate and/or polyol stabilizers, based on the total weight of the aqueous composition, said composition exhibiting a pH higher than 2, lower than 5. At these 5 conditions, the aqueous composition and lactoferrin contained therein may be subjected to a heat treatment without significantly affecting the physiological activity of the lactoferrin. The invention thus particularly pertains to the above aqueous composition, being heat-treated, thus containing heat-stabilized lactoferrin.Type: GrantFiled: June 15, 2009Date of Patent: April 7, 2015Assignee: Campina Nederland Holding B.V.Inventors: Linqiu Cao, Hans Maas
-
Publication number: 20150087582Abstract: Compositions comprising iron-sequestering glycoproteins, chelating agents, stabilizing agents, binding agents, surfactants, fluorides, antimicrobials and a pH adjuster or buffer for the prevention and treatment of oral cavity diseases caused by dental plaque/biofilm, such as dental caries, gingivitis and periodontitis, through anti-infective properties are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive oral bacteria occurring in polymicrobial dental biofilms. The composition may be in the form of wash, rinse, soak, paste, gel, spray, or other suitable form. Additionally, the invention offers an efficient method of delivering the formulated composition containing a PEGylated or fluorinated iron-sequestering glycoprotein and one or two chelating agents or chelating agents alone using either a liposomal or a nanoparticle delivery system.Type: ApplicationFiled: June 27, 2012Publication date: March 26, 2015Inventors: Karen LoVetri, Srinivasa Madhyastha, Nandadeva Yakandawala, Purushottam V. Gawande, Gord Froehlich
-
Patent number: 8968726Abstract: Compositions are described which contain lactoferrin and angiogenin. The described compositions are useful in treatment of a variety of conditions, particularly in promoting bone health and relief of menopausal symptoms.Type: GrantFiled: August 5, 2011Date of Patent: March 3, 2015Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
-
Patent number: 8940687Abstract: Antimicrobial compositions based upon stabilized angiogenin compositions also contain osteopontin and antimicrobial proteins such as lactoperoxidase (LPO), myeloperoxidase (MPO), salivary peroxidase (SPO) and lysozyme.Type: GrantFiled: April 11, 2013Date of Patent: January 27, 2015Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
-
Publication number: 20140357550Abstract: A pharmaceutical composition for treatment of acute toxic conditions relates to the field of medicine, particularly to nanotechnology and toxicology, and can be used for prophylaxis and therapy of various etiologies of toxic states, including the acute ones. The claimed pharmaceutical composition for treatment of acute toxic conditions contains protein—the human lactoferrin—and further comprises of non-replicating nanoparticles with inset of human lactoferrin gene and formulating buffer. The dose of the claimed pharmaceutical composition is 3 ml. The dose of the claimed pharmaceutical composition comprises: human lactoferrin—from 50 to 100 mg; non-replicating nanoparticles—7×1011 virus particle (v.p.); formulating buffer—rest, ml. At the same time, the donor human milk lactoferrin or any human lactoferrin is used as the human lactoferrin.Type: ApplicationFiled: August 14, 2014Publication date: December 4, 2014Inventors: Maksim M. SHMAROV, Raisa I. YAKUBOVSKAYA, Rustam R. ATAULLAKHANOV
-
Publication number: 20140276493Abstract: Provided herein are biologically active solution compositions comprising one or more sacrificial proteolytic enzyme substrates, one or more preservatives, and one or more antimicrobial agents and methods of using the solution compositions to treat tissue sites, in particular chronic wounds. The compositions may be used in conjunction with negative pressure wound therapy to treat tissue sites.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Braden King-Fung Leung, Ona Whelove, Chester R. Edlund, John R. Harper
-
Publication number: 20140255365Abstract: The present disclosure relates to an oral electrolyte solution comprising lactoferrin. Lactoferrin may promote intestinal healing during a bout of diarrhea in a pediatric subject, thereby reducing the duration of diarrhea symptoms. Additionally, the oral electrolyte solutions disclosed herein may comprise Lactobacillus rhamnosus GG, vitamin B3 and/or a source of zinc. The disclosure further relates to methods of reducing the duration of diarrhea symptoms and reducing gastrointestinal irritation in a pediatric subject by providing an oral electrolyte solution comprising lactoferrin.Type: ApplicationFiled: March 11, 2013Publication date: September 11, 2014Applicant: Mead Johnson Nutrition CompanyInventors: Juan M. Gonzalez, Dattatreya Banavara, John Alvey
-
Patent number: 8703699Abstract: A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the mixture.Type: GrantFiled: April 7, 2011Date of Patent: April 22, 2014Assignee: Auckland Uniservices LimitedInventors: Jillian Cornish, Ian Reginald Reid, Kate Patricia Palmano, Neill Ward Haggarty
-
Publication number: 20140072621Abstract: Compositions and methods are provided for treating patients suffering from compromised intestinal function, including inflammatory bowel disease. The method comprises orally administering a composition comprising hyaluronan, where said hyaluronan has a molecular weight within the range of about 35 kDa.Type: ApplicationFiled: May 8, 2012Publication date: March 13, 2014Applicant: THE CLEVELAND CLINIC FOUNDATIONInventors: Carol De La motte, Sean Kessler
-
Patent number: 8648036Abstract: A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source.Type: GrantFiled: December 29, 2010Date of Patent: February 11, 2014Assignee: Mead Johnson Nutrition CompanyInventors: Anja Wittke, Dattatreya Banavara, Cecilia Munoz
-
Patent number: 8592369Abstract: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention.Type: GrantFiled: May 7, 2010Date of Patent: November 26, 2013Assignee: Nestec S.A.Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
-
Publication number: 20130310306Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumours.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicant: PharmaSurgics In Sweden ABInventors: Margit Mahlapuu, Camilla Bjöm, Veronika Sjöstrand, Bjöm Walse, Bo Svenson
-
Publication number: 20130266628Abstract: Composite materials comprising functionalized graphenes, methods of preparing the composite materials, and methods of using the composite materials are described herein. A composite material comprising reduced graphene oxide, chitosan, and native lactoferrin show much higher antimicrobial activity versus individual reduced graphene oxide, chitosan, and native lactoferrin alone.Type: ApplicationFiled: April 10, 2012Publication date: October 10, 2013Applicant: INDIAN INSTITUTE OF TECHNOLOGY MADRASInventors: Pradeep THALAPPIL, Theruvakkattil SREENIVASAN SREEPRASAD, Mundampra MALIYEKKAL SHIHABUDHEEN
-
Patent number: 8524658Abstract: The present invention relates generally to the field of brain development and brain health. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed brain development and/or a delayed development of the nervous system. Also cognitive performance can be increased.Type: GrantFiled: May 7, 2010Date of Patent: September 3, 2013Assignee: Nestec S.A.Inventors: Bing Wang, Magali Faure, Jeroen Schmitt
-
Publication number: 20130210708Abstract: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.Type: ApplicationFiled: April 23, 2013Publication date: August 15, 2013Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventor: UNIVERSITY OF IOWA RESEARCH FOUNDATION
-
Patent number: 8476223Abstract: Formulations are provided for the improvement of sleep patterns. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber such as glucomannan and includes Metallo-Lactoferrin protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions may optionally include additional components such as 5-hydroxy-L-tryptophan (5-HTP), choline, melatonin, milk protein hydrolysate, L-arginine, and L-carnitine. The compositions can be administered orally in a variety of forms.Type: GrantFiled: April 28, 2011Date of Patent: July 2, 2013Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
-
Patent number: 8461106Abstract: This invention relates to methods and compositions capable of inhibiting biofilm formation. Specifically, provided herein are methods and compositions using Lactoferrin for the inhibition of biofilm formation.Type: GrantFiled: July 9, 2008Date of Patent: June 11, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Noam A Cohen, Bert W. O'Malley, Jr., Alexander G. Chiu, James N. Palmer, Jacob D. Steiger
-
Patent number: 8445429Abstract: The present invention relates generally to the field of neuronal health, neuronal protection and neuronal development. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed development of the enteric nervous system. Neuronal cells in the gut can be protected. Disorders linked to a delayed development of the enteric nervous system and/or to an impaired enteric nervous system can be treated or prevented by the administration of lactoferhn containing compositions.Type: GrantFiled: May 7, 2010Date of Patent: May 21, 2013Assignee: Nestec S.A.Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
-
Publication number: 20130064809Abstract: A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor.Type: ApplicationFiled: August 6, 2012Publication date: March 14, 2013Inventor: Jean-Paul PERRAUDIN
-
Patent number: 8343911Abstract: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.Type: GrantFiled: October 20, 2008Date of Patent: January 1, 2013Assignee: University of Iowa Research FoundationInventors: Pradeep K. Singh, Michael J. Welsh, E. Peter Greenberg
-
Patent number: 8334254Abstract: The invention concerns the use of a recombinant nucleotide sequence containing a cDNA coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by the cDNA, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins.Type: GrantFiled: April 8, 2008Date of Patent: December 18, 2012Assignee: EDULISInventors: Dominique Legrand, Valerie Salmon, Genevieve Spik, Veronique Gruber, Philippe Bournat, Bertrand Merot
-
Patent number: 8309080Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.Type: GrantFiled: December 3, 2008Date of Patent: November 13, 2012Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Sreus Naidu, A. G. Tezus Naidu
-
Publication number: 20120245080Abstract: The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.Type: ApplicationFiled: April 15, 2010Publication date: September 27, 2012Applicant: BMG PHARMA LLCInventors: William A. Goolsbee, Jeffrey L. Lillard
-
Publication number: 20120184484Abstract: The present invention relates generally to the field of brain development and brain health. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed brain development and/or a delayed development of the nervous system. Also cognitive performance can be increased.Type: ApplicationFiled: May 7, 2010Publication date: July 19, 2012Applicant: NESTEC S.A.Inventors: Bing Wang, Magali Faure, Jeroen Schmitt
-
Publication number: 20120184483Abstract: The present invention relates generally to the field of neuronal health, neuronal protection and neuronal development. One embodiment of the present invention relates to a composition that can be used for the treatment or prevention of a delayed development of the enteric nervous system. Neuronal cells in the gut can be protected. Disorders linked to a delayed development of the enteric nervous system and/or to an impaired enteric nervous system can be treated or prevented by the administration of lactoferhn containing compositions.Type: ApplicationFiled: May 7, 2010Publication date: July 19, 2012Applicant: NESTEC S.A.Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
-
Publication number: 20120171163Abstract: A method for inhibiting a bacterial invasive mechanism involving administering to a human a nutritional composition including a lipid or fat; a protein source; about 5 to about 100 mg/100 kcal of a source of long chain polyunsaturated fatty acids which comprises docosahexanoic acid; about 0.1 to about 1 g/100 kcal of a prebiotic composition, wherein the prebiotic composition comprises at least 20% of an oligosaccharide; at least about 10 mg/100 kCal of lactoferrin selected from the group consisting of non-human lactoferrin, human lactoferrin produced by a genetically modified organism, and combinations thereof.Type: ApplicationFiled: December 29, 2010Publication date: July 5, 2012Inventors: Anja Wittke, Dattatreya Banavara, Robert J. McMahon, Cecilia Munoz
-
Publication number: 20120172288Abstract: The present disclosure relates to the use of nutritional compositions including lactoferrin produced by a non-human source in supporting resistance to diseases or conditions caused by bacterial and viral pathogens.Type: ApplicationFiled: December 29, 2010Publication date: July 5, 2012Inventors: Anja Wittke, Cecilia Munoz, Dattatreya Banavara
-
Publication number: 20120171176Abstract: A method for inhibiting the adhesion of at least one pathogen in the gastrointestinal tract of a human is disclosed herein. In certain embodiments, the method involves administering to the human a nutritional composition including a fat or lipid source, a protein source, a prebiotic composition that includes galactooligosaccharide and/or polydextrose and lactoferrin produced by a non-human source.Type: ApplicationFiled: December 29, 2010Publication date: July 5, 2012Inventors: Anja Wittke, Dattatreya Banavara, Cecilia Munoz
-
Publication number: 20120142583Abstract: The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm.Type: ApplicationFiled: October 20, 2008Publication date: June 7, 2012Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATIONInventors: Pradeep K. Singh, Michael J. Welsh, Everett P. Greenberg
-
Publication number: 20120122767Abstract: The invention provides biomatrix compositions comprising cross-linked lactoferrin, either alone or in combination with other organic or inorganic components. Also provided are methods of making and using the biomatrix compositions. As described herein, cross-linked lactoferrin biomatrix retains the bioactivities of the lactoferrin molecule. The biomatrix composition can act as a matrix for cell adhesion and growth and is particularly useful in musculoskeletal tissue regeneration. The biomatrix compositions can be pre-formed or injectable and can act as a cell, drug or protein delivery vehicle.Type: ApplicationFiled: May 10, 2011Publication date: May 17, 2012Applicant: University of ConnecticutInventor: Lakshmi Sreedharan Nair
-
Patent number: 8147875Abstract: The invention provides a method for the treatment of acne comprising orally administering to a person suffering from acne an effective amount of a whey protein fraction containing lactoferrin, and preferably containing further specific whey proteins. The lactoferrin is preferably native bovine lactoferrin and the whey protein fraction is administered at a level of between 10 mg and 2 g lactoferrin per patient per day.Type: GrantFiled: March 14, 2006Date of Patent: April 3, 2012Assignee: Campina Nederland Holding B.V.Inventors: Rick De Waard, Angela Loriann Walter
-
Publication number: 20120021071Abstract: The invention relates to the use of a synergistic combination of at least one ion selected from the group including hypothiocyanites and/or hypohalites and of lactoferrin for preparing a pharmaceutical composition for treating cystic fibrosis. In one embodiment, the lactoferrin is one having a purity higher than 95% and substantially free of lipopolysaccharides, endotoxins, and angiogenins, and having an iron saturation level higher than 15%.Type: ApplicationFiled: January 28, 2010Publication date: January 26, 2012Applicant: ALAXIAInventors: Philippe Bordeau, Jean-Paul Perraudin
-
Publication number: 20110301077Abstract: The invention concerns a method for production of lactoferrin comprising at least the steps of: a) disposing of raw material that have not been treated at a temperature greater than 500 C, b) submitting this raw material to a treatment in order to obtain a solution of Lactenin (LN) or Milk Basic Protein (MBP), c) submitting this LN or MBP solution to a step of purification on a cation exchange resin equilibrated with an acetate buffer at a pH between 4 and 9 and eluted with different buffer solutions containing different solute concentrations, d) and collecting a fraction containing Lactoferrin having more than 95% of purity, having no polymers and substantially free of LPS, endotoxins and angiogenin. It also concerns the Lactoferrin obtained having more than 95% of purity, substantially free of LPS, endotoxins and angiogenin with an iron saturation level comprised between 9% to 15%.Type: ApplicationFiled: January 28, 2010Publication date: December 8, 2011Inventor: Jean-Paul Perraudin
-
Patent number: 8021659Abstract: Methods of enhancing the bio-availability of coenzyme Q10, and methods of supporting the cardiovascular system to accommodate the increase in cellular energy synthesis as a result of the bio-availability of coenzyme Q10 are described. Compositions which include coenzyme Q10, lactoferrin and/or angiogenin are described for use in the related methods, for multi-functional health applications.Type: GrantFiled: July 7, 2006Date of Patent: September 20, 2011Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
-
Patent number: 8003603Abstract: Stabilized angiogenin compositions and methods of preparing a stabilized angiogenin compositions by non-covalent immobilization on a naturally occurring substrate, such as a protein, lipid, nucleic acid or nucleotide substrate, are disclosed.Type: GrantFiled: September 4, 2009Date of Patent: August 23, 2011Assignee: Naidu LPInventor: A. Satyanarayan Naidu
-
Publication number: 20110150830Abstract: The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections.Type: ApplicationFiled: February 14, 2011Publication date: June 23, 2011Applicant: WASHINGTON, UNIVERSITY OFInventors: Tomikazu Sasaki, Henry Chiu-Yuen Lai, Narendra Pal Singh, Steve J. Oh
-
Patent number: 7956031Abstract: Formulations are provided for the trigger and release of bioenergy. The formulations generally include a trigger complex, an elemental complex and a coenzyme-vitamin B complex. The trigger complex is high in fiber and includes at least one metal-binding protein in an alkaline buffer system. The elemental complex includes one or more trace element as a suitable salt. The coenzyme-vitamin B complex includes one or more coenzyme, coenzyme precursor and/or B-vitamin. The compositions can be administered orally in a variety of forms.Type: GrantFiled: May 26, 2006Date of Patent: June 7, 2011Assignee: Naidu LPInventors: A. Satyanarayan Naidu, A. G. Tezus Naidu, A. G. Sreus Naidu
-
Publication number: 20110091553Abstract: An object of the present invention is to provide a method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production.Type: ApplicationFiled: June 2, 2009Publication date: April 21, 2011Applicant: KANEKA CORPORATIONInventors: Kento Kanaya, Masao Sato
-
Patent number: 7928185Abstract: The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.Type: GrantFiled: November 10, 2008Date of Patent: April 19, 2011Assignee: PharmaSurgics in Sweden ABInventors: Inger Mattsby-Baltzer, Gunnar Dolphin
-
Patent number: 7890602Abstract: The present inventions may be implemented by tools enabling preferred domain positioning on a registration website. An example may comprise a computer-readable media storing instructions that, when executed by a server computer, cause the server to receive a bid from a registry seeking such preferred placement for a domain (that may be administered by the registry), generate a quality score for the domain, and determine the preferred placement based upon the bid and the quality score.Type: GrantFiled: December 11, 2009Date of Patent: February 15, 2011Assignee: The Go Daddy Group, Inc.Inventors: Robert Parsons, Barbara Rechterman, Micheal Zimmerman, James Bladel, Richard Merdinger
-
Publication number: 20110009313Abstract: A method of producing a polyethylene glycolated (PEGylated) lactoferrin complex having a linear polyethylene glycol (PEG) or a modified product thereof covalently bonded to lactoferrin via an amide bond includes causing a reaction to occur in a reaction liquid, which contains the lactoferrin and a linear PEG derivative having a para-nitrophenol leaving group, under conditions that allow formation of an amide group between the PEG derivative and the lactoferrin. A PEGylated lactoferrin complex contains a linear PEG or a modified product thereof covalently bonded to lactoferrin via an amide bond, and a pharmaceutical composition includes a PEGlyated lactoferrin complex, a therapeutically inert base, and/or an additive.Type: ApplicationFiled: March 13, 2009Publication date: January 13, 2011Applicant: NRL PHARMA, INC.Inventor: Atsushi Sato
-
Publication number: 20100322872Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.Type: ApplicationFiled: August 3, 2010Publication date: December 23, 2010Inventor: Jean-Paul Perraudin
-
Publication number: 20100298208Abstract: This invention relates to methods and compositions capable of inhibiting biofilm formation. Specifically, provided herein are methods and compositions using Lactoferrin for the inhibition of biofilm formation.Type: ApplicationFiled: July 9, 2008Publication date: November 25, 2010Inventors: Noam A Cohen, Bert W. O'Malley, JR., Alexander G. Chiu, James N. Palmer, Jacob D. Steiger